Takeda (TAK) chief communications officer receives 18,808 RSU share award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Smoter Jennifer Marie reported acquisition or exercise transactions in this Form 4 filing.

Takeda Pharmaceutical reported that Chief Communications & Government Officer Jennifer Marie Smoter received an equity award in the form of 18,808 American Depositary Shares through a grant of restricted stock units (RSUs). Each RSU represents a contingent right to receive one ADS at no purchase price.

The RSUs vest in three equal annual installments beginning on July 1, 2027, tying the full value of the award to continued service and future vesting dates. Following this award, Smoter is shown as directly holding 18,808 ADS, reflecting a compensation-related equity grant rather than any open‑market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Smoter Jennifer Marie

Role Chief Comm. & Gov. Officer

Type	Security	Shares	Price	Value
Grant/Award	American Depositary Shares	18,808	$0.00	--

Holdings After Transaction: American Depositary Shares — 18,808 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 18,808 shares Grant price per ADS: $0.0000 per share Shares held after grant: 18,808 shares +2 more

5 metrics

RSUs granted 18,808 shares Restricted stock unit award linked to American Depositary Shares

Grant price per ADS $0.0000 per share Stated price for RSU-linked American Depositary Shares

Shares held after grant 18,808 shares Total American Depositary Shares following the transaction

Vesting installments 3 equal tranches RSUs vest in three equal annual installments

Vesting start date July 1, 2027 First vesting date for the RSU award

Key Terms

restricted stock units (RSUs), American Depositary Shares, grant/award acquisition, Chief Comm. & Gov. Officer

4 terms

restricted stock units (RSUs) financial

"Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

American Depositary Shares financial

"Each RSU represents a contingent right to receive one American Depositary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

Chief Comm. & Gov. Officer financial

"officer_title": "Chief Comm. & Gov. Officer""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/06/2026 - 06:08 PM Accepted by SEC EDGAR 07/06/2026 - 06:07 PM

FAQ

What insider transaction did TAK report for Jennifer Marie Smoter?

Takeda Pharmaceutical reported that executive Jennifer Marie Smoter received an equity grant of 18,808 restricted stock units. Each RSU corresponds to one American Depositary Share, providing stock-based compensation without an open-market purchase or sale of existing TAK shares.

How many Takeda (TAK) shares were granted in this Form 4 filing?

The filing shows a grant of 18,808 restricted stock units tied to Takeda American Depositary Shares. After the award, Smoter’s direct holdings are reported as 18,808 ADS, reflecting the full size of this compensation-related equity grant.

At what price were the Takeda (TAK) RSUs granted to the executive?

The RSUs were granted at a stated price of $0.0000 per American Depositary Share. This indicates a stock-based compensation award, not an open-market purchase, and means the executive is not paying cash to acquire the underlying ADS on vesting.

When do Jennifer Smoter’s Takeda (TAK) RSUs start vesting?

The RSUs begin vesting on July 1, 2027, in three equal annual installments. This schedule links the executive’s potential share delivery to continued service over multiple years, spreading the compensation impact across future vesting dates.

Is the Takeda (TAK) Form 4 transaction a buy or a grant?

The transaction is classified as a grant or award acquisition, coded as “A” on the Form 4. It represents restricted stock units being awarded as compensation, rather than the executive buying or selling Takeda shares in the open market.

What total TAK holdings does the Form 4 show after the RSU grant?

After the grant, total shares following the transaction are reported as 18,808 American Depositary Shares. This figure reflects Smoter’s direct position associated with the RSU award disclosed in this Form 4 filing for Takeda Pharmaceutical.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smoter Jennifer Marie

(Last)

(First)

(Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Comm. & Gov. Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
American Depositary Shares	07/01/2026		A⁽¹⁾		18,808	A	$0	18,808	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest in three equal annual installments beginning on July 1, 2027.

Remarks:

	/s/ Kate Huleatt, by power of attorney, for Jennifer M. Smoter	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR